Venus Remedies Latest Share Price (VENUSREM)
TODAY IN ONE LINE
With a market cap of ₹2,305.94 Cr., it trades at a P/E of 20.10. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Venus Remedies flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 126.4% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 21.4% and Profit up 687.0%
- ●Strong Return on EquityHealthy ROE of 15.5%
- ●Healthy Operating MarginsOPM is structurally strong at 17.4%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 23.8% outpacing sales growth of 7.7%
Latest Venus Remedies News
What changed recently?
Recent events, corporate actions, and announcements.
Venus Remedies Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Venus Remedies Limited, framed against the sector median so the premium or discount is obvious at a glance.
Venus Remedies Limited trades at a P/E of 20.10× and P/B of 3.52×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Venus Remedies Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Venus Remedies Limited — derived from the latest tape, not yesterday's close.
Venus Remedies Limited last traded at ₹1,797.5 with an intraday range of ₹1,706.8–₹1,800.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1797.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2017.93 | +220.43 | +12.26% |
| R3 | 1923.93 | +126.43 | +7.03% |
| R2 | 1862.37 | +64.87 | +3.61% |
| R1 | 1829.93 | +32.43 | +1.80% |
| PIVOT | 1768.37 | -29.13 | -1.62% |
| CURRENT | 1797.50 | — | — |
| S1 | 1735.93 | -61.57 | -3.43% |
| S2 | 1674.37 | -123.13 | -6.85% |
| S3 | 1641.93 | -155.57 | -8.65% |
| S4 | 1547.93 | -249.57 | -13.88% |
VENUSREM is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Above opening range, showing Bullishness
Venus Remedies Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Venus Remedies Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Venus Remedies Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,305.94 Cr. and reported EPS of ₹76.93.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 648 | 770 ▲ 18.8% |
| Sales Growth YoY %Derived | 7.72% | 18.79% |
| Other Income | 21 | 13 ▼ 40.0% |
| Total Income | 669 | 782 ▲ 16.9% |
| 379 | 387 ▲ 2.3% | |
| Gross ProfitDerived | 269 | 382 ▲ 42.0% |
| Gross Margin %Derived | 41.56% | 49.68% |
| 206 | 235 ▲ 14.3% | |
| EBITDA (Operating Profit)Derived | 64 | 147 ▲ 131.8% |
| OPM %Derived | 9.81% | 19.14% |
| 32 | 26 ▼ 20.9% | |
| Profit Before Tax (PBT) | 72 | 134 ▲ 86.8% |
| 24 | 31 ▲ 33.0% | |
| Effective Tax %Derived | 32.83% | 23.38% |
| Total Profit for Period | 45 | 103 ▲ 126.8% |
| Net Profit (Owner's PAT)Derived | 45 | 103 ▲ 126.8% |
| Net Profit Margin %Derived | 7.00% | 13.35% |
| PAT Growth YoY %Derived | 59.04% | 126.79% |
| Earnings Per Share (EPS ₹) | 33.90 | 76.89 ▲ 126.8% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 101.5% |
| Total Expenses (incl. D&A & Interest) | 597 | 648 ▲ 8.5% |
| Material Cost % of RevenueDerived | 53.83% | 50.41% |
| Employee Cost % of RevenueDerived | 12.42% | 11.52% |
| Other Cost % of RevenueDerived | 19.33% | 19.02% |
| Interest Coverage (x)Derived | 586.14x | 3,040.25x |
| Period | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 372 | 341 ▼ 8.3% | 548 ▲ 60.5% | 599 ▲ 9.2% | 556 ▼ 7.2% | 601 ▲ 8.3% | 648 ▲ 7.7% | 770 ▲ 18.8% | |
| Sales Growth YoY %Derived | — | — | 60.52% | 9.22% | -7.21% | 8.27% | 7.72% | 18.79% | |
| Other Income | 2 | 5 ▲ 135.4% | 20 ▲ 269.8% | 8 ▼ 57.7% | 10 ▲ 24.2% | 12 ▲ 12.2% | 21 ▲ 81.0% | 13 ▼ 40.0% | |
| Total Income | 375 | 347 ▼ 7.4% | 568 ▲ 63.7% | 607 ▲ 6.9% | 566 ▼ 6.8% | 613 ▲ 8.3% | 669 ▲ 9.1% | 782 ▲ 16.9% | |
205 | 174 ▼ 15.0% | 341 ▲ 95.5% | 385 ▲ 13.1% | 331 ▼ 14.1% | 355 ▲ 7.2% | 379 ▲ 6.7% | 387 ▲ 2.3% | ||
| Gross ProfitDerived | 167 | 167 ▼ 0.1% | 207 ▲ 24.0% | 213 ▲ 2.8% | 225 ▲ 5.3% | 247 ▲ 9.9% | 269 ▲ 9.1% | 382 ▲ 42.0% | |
| Gross Margin %Derived | 44.93% | 48.95% | 37.83% | 35.61% | 40.42% | 41.03% | 41.56% | 49.68% | |
128 | 126 ▼ 1.2% | 154 ▲ 21.5% | 151 ▼ 1.6% | 164 ▲ 8.8% | 187 ▲ 13.9% | 206 ▲ 9.9% | 235 ▲ 14.3% | ||
| EBITDA (Operating Profit)Derived | 39 | 41 ▲ 3.4% | 54 ▲ 31.7% | 62 ▲ 15.5% | 60 ▼ 3.1% | 60 ▼ 1.0% | 64 ▲ 6.6% | 147 ▲ 131.8% | |
| OPM %Derived | 10.60% | 11.95% | 9.81% | 10.38% | 10.84% | 9.91% | 9.81% | 19.14% | |
69 | 37 ▼ 47.2% | 72 ▲ 96.3% | 34 ▼ 52.6% | 33 ▼ 4.2% | 27 ▼ 18.6% | 32 ▲ 22.4% | 26 ▼ 20.9% | ||
| Profit Before Tax (PBT) | -28 | -8 ▲ 70.8% | 49 ▲ 704.3% | 36 ▼ 25.0% | 38 ▲ 4.2% | 45 ▲ 17.7% | 72 ▲ 60.9% | 134 ▲ 86.8% | |
3 | 2 ▼ 37.8% | -13 ▼ 772.7% | -4 ▲ 67.3% | 11 ▲ 363.2% | 16 ▲ 42.2% | 24 ▲ 46.0% | 31 ▲ 33.0% | ||
| Effective Tax %Derived | -11.48% | -24.45% | -27.21% | -11.85% | 29.95% | 36.17% | 32.83% | 23.38% | |
| Total Profit for Period | -31 | -10 ▲ 67.4% | 62 ▲ 717.8% | 41 ▼ 34.1% | 27 ▼ 34.8% | 28 ▲ 7.2% | 45 ▲ 59.0% | 103 ▲ 126.8% | |
| Net Profit (Owner's PAT)Derived | -31 | -10 ▲ 67.4% | 62 ▲ 717.8% | 41 ▼ 34.1% | 27 ▼ 34.8% | 28 ▲ 7.2% | 45 ▲ 59.0% | 103 ▲ 126.8% | |
| Net Profit Margin %Derived | -8.24% | -2.93% | 11.27% | 6.80% | 4.78% | 4.74% | 7.00% | 13.35% | |
| PAT Growth YoY %Derived | — | — | 717.77% | -34.07% | -34.76% | 7.25% | 59.04% | 126.79% | |
| Earnings Per Share (EPS ₹) | -24.87 | -8.10 ▲ 67.4% | 50.04 ▲ 717.8% | 30.47 ▼ 39.1% | 19.88 ▼ 34.8% | 21.32 ▲ 7.2% | 33.90 ▲ 59.0% | 76.89 ▲ 126.8% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 8.3% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 237.2% | -0 ▲ 79.9% | -1 ▼ 491.6% | -7 ▼ 1094.0% | -1 ▲ 80.9% | -1 ▲ 46.9% | 0 ▲ 101.5% | |
| Total Expenses (incl. D&A & Interest) | 402 | 355 ▼ 11.8% | 519 ▲ 46.3% | 571 ▲ 9.9% | 528 ▼ 7.5% | 568 ▲ 7.7% | 597 ▲ 5.0% | 648 ▲ 8.5% | |
| Material Cost % of RevenueDerived | 55.00% | 49.33% | 63.48% | 63.81% | 57.21% | 57.24% | 53.83% | 50.41% | |
| Employee Cost % of RevenueDerived | 10.56% | 13.48% | 8.40% | 8.74% | 11.04% | 11.89% | 12.42% | 11.52% | |
| Other Cost % of RevenueDerived | 23.78% | 23.52% | 19.62% | 16.50% | 18.54% | 19.23% | 19.33% | 19.02% | |
| Interest Coverage (x)Derived | 0.16x | 0.66x | 1.42x | 59.42x | 96.21x | 352.77x | 586.14x | 3,040.25x |
Venus Remedies segment analysis : revenue and profit mix.
Disclosed business segments at Venus Remedies with their share of revenue and profit, switchable between consolidated and standalone reporting.
Venus Remedies discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Venus Remedies Limited.
Our AI distills the core fundamental drivers supporting Venus Remedies Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Venus Remedies Limited's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Zero debt-to-equity ratio indicates strong financial stability and low leverage.
Exceptional quarterly profit growth of 687.00% reflects strong operational performance.
Robust quarterly sales growth of 21.40% indicates increasing demand and market penetration.
Attractive P/E ratio of 11.01 suggests potential undervaluation compared to peers.
Diversified product portfolio across critical care and herbal medicine segments.
Key Risks.
Relatively low ROE (4.64%) and ROCE (11.10%) indicate scope for efficiency.
Absence of dividend yield (0.00%) may deter income-focused investors.
Stagnant 5-year EPS growth of 0.00% indicates lack of long-term earnings expansion.
Negative 5-year Free Operating Cash Flow CAGR of -0.42% is concerning.
Current stock price significantly below 52-week high suggests recent downtrend.
Flip Conditions.
Valuation risk. a P/E above 26 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 10% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.28%.
Venus Remedies Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Venus Remedies Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Venus Remedies Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Venus Remedies Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Venus Remedies Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Venus Remedies Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Venus Remedies Limited stood at 44.1% of traded volume, against a 20-day average of 65.6%.
Venus Remedies announcements: results, concalls, ratings, M&A.
Filings Venus Remedies sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Venus Remedies files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 76 documents below.
Shareholders meeting
Voting Results and Scrutinizer's report. Earlier submitted file was not machine readable.
Shareholders meeting
Venus Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 20, 2026. Further, the company…
Amendment to AOA/MOA
Venus Remedies Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Appointment
Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. Gurminder Singh Bedi as Non- Executive Independent Director of the…
Shareholders meeting
Venus Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 20, 2026
Venus Remedies dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Venus Remedies has declared, sequenced by announce and record date.
Venus Remedies corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Venus Remedies Limited: business, sector, key facts.
What Venus Remedies Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Venus Remedies Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: VENUSREM, BSE: 526953.
Venus Remedies Limited is a pharmaceutical company headquartered in Panchkula, India, operating both domestically and internationally. Their core business revolves around the research, development, manufacturing, and distribution of a wide array of pharmaceutical products.
The company's product portfolio spans a diverse range of therapeutic areas, catering to a broad spectrum of medical needs. These therapeutic areas include, but are not limited to: analgesics (pain relievers), antipyretics (fever reducers), anti-diabetics, antibiotics, antiemetics (anti-nausea medications), antivirals, cardiovascular medications, disinfectants and antiseptics, gastrointestinal therapies, hepatoprotective agents (liver protectants), hormone therapies, immunostimulants, iron supplements, muscle relaxants, neurological medications, oncology medications, respiratory medications, and anticoagulants (blood thinners).
Beyond conventional pharmaceuticals, Venus Remedies also maintains a significant presence in the herbal medicine market, offering a portfolio of products derived from natural sources. This demonstrates a commitment to providing diverse treatment options and potentially catering to a broader consumer base interested in alternative or complementary therapies.
Established in 1989, Venus Remedies has a history of nearly three and a half decades in the pharmaceutical industry. This longevity suggests a degree of stability and market experience, although the specific details of their market share and financial performance would require further information beyond the provided text.
In summary, Venus Remedies' business model is built upon a diversified product portfolio encompassing both conventional and herbal pharmaceuticals, targeting a wide array of therapeutic areas and serving both domestic and international markets. Their long operational history suggests established processes and infrastructure within the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about Venus Remedies Limited (VENUSREM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Venus Remedies Limited (VENUSREM)?
The current share price of Venus Remedies Limited (VENUSREM) is ₹1,797.50. Today, the stock has gained by ₹82.40 (4.8%), trading in a range of ₹1,706.80 to ₹1,800.80. The stock opened at ₹1,749.90 with a trading volume of 2,46,228 shares.
02Is Venus Remedies Limited stock a good investment for long-term?
Venus Remedies Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,305.94 Cr., P/E ratio of 20.1, ROE of 15.48%, and ROCE of 11.1%. The dividend yield stands at 0.56%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Venus Remedies Limited stock?
The 52-week high price of Venus Remedies Limited (VENUSREM) is ₹1,800.80, while the 52-week low is ₹424.00. Currently trading at ₹1,797.50, the stock is 323.94% above its 52-week low and 0.18% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Venus Remedies Limited stock at the current price?
Whether to buy Venus Remedies Limited stock at ₹1,797.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.1 and P/B ratio of 3.52. Today's performance shows a gain of 4.8%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Venus Remedies Limited and when is the next dividend?
Venus Remedies Limited offers a dividend yield of 0.56%, which means for every ₹100 invested at the current price of ₹1,797.50, you can expect to receive approximately ₹0.56 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Venus Remedies Limited?
Venus Remedies Limited's key financial metrics include: P/E Ratio: 20.1, P/B Ratio: 3.52, ROE: 15.48%, ROCE: 11.1%, Dividend Yield: 0.56%, EPS: ₹76.93, Book Value: ₹444.63, and Debt-to-Equity: 0. The company's market cap stands at ₹2,305.94 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Venus Remedies Limited stock performing today in the market?
Venus Remedies Limited stock opened at ₹1,749.90 and is currently trading at ₹1,797.50, showing a gain of ₹82.40 (4.8%). The intraday high is ₹1,800.80 and low is ₹1,706.80. The trading volume stands at 2,46,228 shares, indicating moderate market participation today.
08What is the P/E ratio of Venus Remedies Limited and what does it indicate?
Venus Remedies Limited has a Price-to-Earnings (P/E) ratio of 20.1, which means investors are willing to pay 20.10 for every ₹1 of earnings. With an EPS of ₹76.93, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Venus Remedies Limited (VENUSREM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.